Skip to navigation Skip to content

Clinical Trial: High-Dose Biotin (MD1003)

Share

Details
Type of MS: PPMS|SPMS
Treatment mode of action: To protect nervous system
Number of Subjects: 600
Medication: High-Dose Biotin (MD1003)
Location: Arizona|California|Colorado|Connecticut|Florida|Illinois|Kansas|Maryland|Massachusetts|Michigan|Missouri|New Jersey|New Mexico|New York|North Carolina|Ohio|Oregon|Pennsylvania|Tennessee|Texas|Utah|Virginia|Washington
Institutions: Multiple, worldwide Contact Information
Dr. Robert Lasser, www.spi2study.com
617-378-8701

Funding:

MedDay

Description

Investigators worldwide are conducting a clinical trial testing high-dose biotin (MD1003, MedDay Pharmaceuticals SA) versus inactive placebo in 600 people with secondary or primary progressive MS. Participants can remain on existing disease-modifying treatments (such as ocrelizumab), if treatment has been stable for at least 90 days prior to enrollment. Please visit www.spi2study.com

Share


Your input is important!

We believe that people affected by MS live better lives when they're connected.  To help us provide you with the best resources, support and information, please provide your feedback in a short survey.
Take the survey